Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice StatementSriram Deivasigamani, Ali Kasraeian, Srinath Kotamarti et al.|European Urology|2023Cited by 42
A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE TrialArvin K. George, Jonathan Coleman, Ranko Miocinovic et al.|Cancers|2024Cited by 15
Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE TrialArvin K. George, Jonathan Coleman, Brian T. Helfand et al.|European Urology|2025Cited by 15
IP37-18 LOWER URINARY TRACT SYMPTOM IMPROVEMENT AFTER FOCAL IRREVERSIBLE ELECTROPORATION FOR LOCALIZED PROSTATE CANCER: 12-MONTH PRESERVE TRIAL RESULTSSoum D. Lokeshwar, Arvin K. George, Jessica Ramirez et al.|The Journal of Urology|2026Cited by 0
IP37-19 IMPACT OF IRREVERSIBLE ELECTROPORATION ON SEXUAL FUNCTION: AN ANALYSIS OF THE PRESERVE TRIALSoum D. Lokeshwar, Arvin K. George, Jessica Ramirez et al.|The Journal of Urology|2026Cited by 0